Literature DB >> 21439347

Gene-environment interactions: key to unraveling the mystery of Parkinson's disease.

Hui-Ming Gao1, Jau-Shyong Hong.   

Abstract

Parkinson's disease (PD) is the second most common neurodegenerative disease. The gradual, irreversible loss of dopamine neurons in the substantia nigra is the signature lesion of PD. Clinical symptoms of PD become apparent when 50-60% of nigral dopamine neurons are lost. PD progresses insidiously for 5-7 years (preclinical period) and then continues to worsen even under the symptomatic treatment. To determine what triggers the disease onset and what drives the chronic, self-propelling neurodegenerative process becomes critical and urgent, since lack of such knowledge impedes the discovery of effective treatments to retard PD progression. At present, available therapeutics only temporarily relieve PD symptoms. While the identification of causative gene defects in familial PD uncovers important genetic influences in this disease, the majority of PD cases are sporadic and idiopathic. The current consensus suggests that PD develops from multiple risk factors including aging, genetic predisposition, and environmental exposure. Here, we briefly review research on the genetic and environmental causes of PD. We also summarize very recent genome-wide association studies on risk gene polymorphisms in the emergence of PD. We highlight the new converging evidence on gene-environment interplay in the development of PD with an emphasis on newly developed multiple-hit PD models involving both genetic lesions and environmental triggers. Published by Elsevier Ltd.

Entities:  

Mesh:

Year:  2011        PMID: 21439347      PMCID: PMC3098527          DOI: 10.1016/j.pneurobio.2011.03.005

Source DB:  PubMed          Journal:  Prog Neurobiol        ISSN: 0301-0082            Impact factor:   11.685


  315 in total

1.  A Drosophila model of mutant human parkin-induced toxicity demonstrates selective loss of dopaminergic neurons and dependence on cellular dopamine.

Authors:  Tzu-Kang Sang; Hui-Yun Chang; George M Lawless; Anuradha Ratnaparkhi; Lisa Mee; Larry C Ackerson; Nigel T Maidment; David E Krantz; George R Jackson
Journal:  J Neurosci       Date:  2007-01-31       Impact factor: 6.167

2.  Rare heterozygous parkin variants in French early-onset Parkinson disease patients and controls.

Authors:  S Lesage; E Lohmann; F Tison; F Durif; A Dürr; A Brice
Journal:  J Med Genet       Date:  2007-08-31       Impact factor: 6.318

3.  Loss-of-function of human PINK1 results in mitochondrial pathology and can be rescued by parkin.

Authors:  Nicole Exner; Bettina Treske; Dominik Paquet; Kira Holmström; Carola Schiesling; Suzana Gispert; Iria Carballo-Carbajal; Daniela Berg; Hans-Hermann Hoepken; Thomas Gasser; Rejko Krüger; Konstanze F Winklhofer; Frank Vogel; Andreas S Reichert; Georg Auburger; Philipp J Kahle; Bettina Schmid; Christian Haass
Journal:  J Neurosci       Date:  2007-11-07       Impact factor: 6.167

4.  The Parkinson's disease protein alpha-synuclein disrupts cellular Rab homeostasis.

Authors:  Aaron D Gitler; Brooke J Bevis; James Shorter; Katherine E Strathearn; Shusei Hamamichi; Linhui Julie Su; Kim A Caldwell; Guy A Caldwell; Jean-Christophe Rochet; J Michael McCaffery; Charles Barlowe; Susan Lindquist
Journal:  Proc Natl Acad Sci U S A       Date:  2007-12-27       Impact factor: 11.205

5.  Peripheral inflammatory biomarkers and risk of Parkinson's disease.

Authors:  Honglei Chen; Eilis J O'Reilly; Michael A Schwarzschild; Alberto Ascherio
Journal:  Am J Epidemiol       Date:  2007-09-22       Impact factor: 4.897

Review 6.  Human infection with highly pathogenic H5N1 influenza virus.

Authors:  Andrea Gambotto; Simon M Barratt-Boyes; Menno D de Jong; Gabriele Neumann; Yoshihiro Kawaoka
Journal:  Lancet       Date:  2008-04-26       Impact factor: 79.321

Review 7.  In vivo alpha-synuclein overexpression in rodents: a useful model of Parkinson's disease?

Authors:  Marie-Francoise Chesselet
Journal:  Exp Neurol       Date:  2007-08-23       Impact factor: 5.330

8.  The mitochondrial protease HtrA2 is regulated by Parkinson's disease-associated kinase PINK1.

Authors:  Hélène Plun-Favreau; Kristina Klupsch; Nicoleta Moisoi; Sonia Gandhi; Svend Kjaer; David Frith; Kirsten Harvey; Emma Deas; Robert J Harvey; Neil McDonald; Nicholas W Wood; L Miguel Martins; Julian Downward
Journal:  Nat Cell Biol       Date:  2007-09-30       Impact factor: 28.824

9.  alpha-Synuclein gene duplication is present in sporadic Parkinson disease.

Authors:  T-B Ahn; S Y Kim; J Y Kim; S-S Park; D S Lee; H J Min; Y K Kim; S E Kim; J-M Kim; H-J Kim; J Cho; B S Jeon
Journal:  Neurology       Date:  2007-07-11       Impact factor: 9.910

10.  Late onset sporadic Parkinson's disease caused by PINK1 mutations: clinical and functional study.

Authors:  Vania Gelmetti; Alessandro Ferraris; Livia Brusa; Francesca Romano; Federica Lombardi; Chiara Barzaghi; Paolo Stanzione; Barbara Garavaglia; Bruno Dallapiccola; Enza Maria Valente
Journal:  Mov Disord       Date:  2008-04-30       Impact factor: 10.338

View more
  59 in total

Review 1.  Using DNA methylation to understand biological consequences of genetic variability.

Authors:  Dena G Hernandez; Andrew B Singleton
Journal:  Neurodegener Dis       Date:  2011-11-26       Impact factor: 2.977

Review 2.  NADPH oxidases: novel therapeutic targets for neurodegenerative diseases.

Authors:  Hui-Ming Gao; Hui Zhou; Jau-Shyong Hong
Journal:  Trends Pharmacol Sci       Date:  2012-04-11       Impact factor: 14.819

3.  Alterations of gene expression of sodium channels in dorsal root ganglion neurons of estrogen receptor knockout (ERKO) mice induced by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP).

Authors:  Haixia Ding; Qiang Wang; Jingli Liu; Wenyi Qian; Wenjuan Wang; Jun Wang; Rong Gao; Hang Xiao
Journal:  Endocrine       Date:  2012-02-28       Impact factor: 3.633

Review 4.  How can we improve clinical trials in amyotrophic lateral sclerosis?

Authors:  Paul H Gordon; Vincent Meininger
Journal:  Nat Rev Neurol       Date:  2011-09-27       Impact factor: 42.937

Review 5.  Rodent models and contemporary molecular techniques: notable feats yet incomplete explanations of Parkinson's disease pathogenesis.

Authors:  Sharawan Yadav; Anubhuti Dixit; Sonal Agrawal; Ashish Singh; Garima Srivastava; Anand Kumar Singh; Pramod Kumar Srivastava; Om Prakash; Mahendra Pratap Singh
Journal:  Mol Neurobiol       Date:  2012-06-27       Impact factor: 5.590

Review 6.  Industrial toxicants and Parkinson's disease.

Authors:  W Michael Caudle; Thomas S Guillot; Carlos R Lazo; Gary W Miller
Journal:  Neurotoxicology       Date:  2012-01-30       Impact factor: 4.294

7.  Astrocytes Surviving Severe Stress Can Still Protect Neighboring Neurons from Proteotoxic Injury.

Authors:  Amanda M Gleixner; Jessica M Posimo; Deepti B Pant; Matthew P Henderson; Rehana K Leak
Journal:  Mol Neurobiol       Date:  2015-09-15       Impact factor: 5.590

8.  Advances in the treatment of visual hallucinations in neurodegenerative diseases.

Authors:  Daniel Collerton; John-Paul Taylor
Journal:  Future Neurol       Date:  2013-07

Review 9.  Parkinson's disease: what the model systems have taught us so far.

Authors:  Swagata Ghatak; Dorit Trudler; Nima Dolatabadi; Rajesh Ambasudhan
Journal:  J Genet       Date:  2018-07       Impact factor: 1.166

10.  A 5-Year Follow-up Study on the Relationship between Obstructive Sleep Apnea and Parkinson Disease.

Authors:  Jau-Jiuan Sheu; Hsin-Chien Lee; Herng-Ching Lin; Li-Ting Kao; Shiu-Dong Chung
Journal:  J Clin Sleep Med       Date:  2015-12-15       Impact factor: 4.062

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.